$APLIF News

Last published 1y ago

1y agoAPLIF TSX:APLISaptalis Pharmaceuticals Announces the Launch of LIKMEZ® — The First and Only US FDA-Approved Ready-to-Use Oral Suspension of MetronidazoleBusiness WireSaptalis Pharmaceuticals LLC proudly announces the launch of LIKMEZ® (metronidazole) oral suspension, 500 mg/5 mL (100 mg/ mL), an innovative liquid formulation developed specifically for patients with difficulty
2y agoADTX APLIF TSX:APLIAditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)Business WireAssets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation Aditxt, Inc.
2y agoAPLIF TSX:APLIAppili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge LoanBusiness WirePatent coverage provides drug market exclusivity through at least 2039 Pre-IND meeting with the FDA granted to discuss ATI-1701's regulatory, CMC, toxicology, and Phase 1 strategies Appili Therapeutics Inc.
2y agoAPLIF TSX:APLIAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024Business WireFDA approves ATI-1501 for Metronidazole Oral Suspension 500mg/5mL and its brand name LIKMEZ™ Appili received an additional funding commitment from the U.S. Air Force Academy for ATI-1701, bringing the total
3y agoAPLIF TSX:APLIAppili Therapeutics' Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force AcademyBusiness WireAdditional US$6.6 million funding commitment for ATI-1701 brings the total program funding awarded to approximately US$14 million These funds along with other potential funding sources, are anticipated to continue to
3y agoAPLIF TSX:APLIAppili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate UpdateBusiness WireAppili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual
3y agoAPLIF TSX:APLIAppili Therapeutics Presents at the 10th International Tularemia ConferenceBusiness WireRecently announced Funding Commitment from U.S. Air Force is expected to advance ATI-1701 Biodefense Vaccine Candidate to IND Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), a
3y agoAPLIF TSX:APLIAppili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral SuspensionBusiness WireFDA approves LIKMEZ as the brand name for Metronidazole Oral Suspension (LIKMEZ is a Trademark of Saptalis Pharmaceuticals, LLC) Currently LIKMEZ is the only liquid oral suspension of metronidazole approved in the
3y agoAPLIF TSX:APLIAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024Business WireFDA established a PDUFA action date for ATI-1501 of September 23, 2023 Government funding committed to enable Appili to advance its biodefense vaccine candidate ATI-1701 towards an IND Appili Therapeutics Inc.
3y agoAPLIF TSX:APLIAppili Therapeutics – Press Release CorrectionBusiness WireAppili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), announced today a correction to its press release entitled "Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results"
3y agoAPLIF TSX:APLIAppili Therapeutics Reports Fiscal Year 2023 Financial and Operational ResultsBusiness WireExecuted US$7.3M initial contract with U.S. Air Force Academy for ATI-1701 Upcoming PDUFA date of September 23, 2023 for ATI-1501 Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), a
3y agoAPLIF TSX:APLIAppili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of MetronidazoleBusiness WireUpcoming PDUFA date of September 23, 2023 Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense,
3y agoAPLIF TSX:APLI TSXV:APLIAppili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceBusiness WireAppili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Dr. Don Cilla, Appili
3y agoAPLIF TSX:APLIAppili Therapeutics Appoints Dr. Gary Nabors as Chief Development OfficerBusiness WireAccomplished biopharmaceutical executive brings more than 25 years of experience leading vaccine and antibody product development for infectious disease indications Dr. Nabors representing Appili at the World Vaccine
3y agoAPLIF TSX:APLIAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023Business WireAppili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational
3y agoAPLIF TSX:APLIAppili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine ProgramBusiness WireAppili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program. Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF)
3y agoAPLIF TSX:APLIAppili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of MetronidazoleBusiness WireAnticipated new patent strengthens ATI-1501's potential position as a more convenient alternative treatment option for metronidazole prescriptions on the market. Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the
3y agoAPLIF TSX:APLIAppili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force AcademyBusiness WireDr. Armand Balboni appointed as Chair of the Board and moves to the U.S. Air Force Academy to take over as Principal Investigator for the ATI-1701 program; and Dr. Don Cilla promoted to President and Chief Executive
4y agoAPLIF TSX:APLIAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023Business WireAppili completes strategic reprioritization of programs to focus on ATI-1701, a biodefense tularemia vaccine candidate, ATI-1801, a topical antiparasitic product for the treatment of a disfiguring disease, and ATI-1501,
4y agoAPLIF TSX:APLIAppili Therapeutics Announces Results of Annual and Special Meeting of ShareholdersBusiness WireAppili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders
4y agoAPLIF TSX:APLIAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023Business WireAppili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of
4y agoAPLIF TSX:APLIAppili Therapeutics to Present at WorldLeish7 Conference in Cartagena, ColumbiaBusiness WireAppili to present update on topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease, cutaneous leishmaniasis, in Phase 3 study Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company"
4y agoAPLIF TSX:APLIAppili Therapeutics Reports Fiscal Year 2022 Financial and Operational ResultsBusiness WireAppili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended
4y agoAPLIF TSX:APLIAppili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor ConferenceBusiness WireAppili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stéphane Paquette, Vice President, Corporate Development, will present a
4y agoAPLIF TSX:APLIAppili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous LeishmaniasisBusiness WireTopical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease in Phase 3 study ATI-1801 may be eligible for tropical disease priority review voucher if approved by FDA Appili Therapeutics Inc. (
4y agoAPLIFAppili Therapeutics to Present Live via Webcast at OTC Markets Virtual Life Sciences Investor ForumGlobeNewswireCompany to provide update on drug development pipeline including recently announced US Department of Defense funding for biodefense vaccine candidate ATI-1701 Presentation scheduled for 2:30 pm ET on Thursday, March 10, 2022 HALIFAX, Nova S
4y agoAPLIF TSX:APLIAppili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701Business WireFunds to advance ATI-1701 to IND submission Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the U.S. Department of Def
4y agoAPLIF TSX:APLIAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022Business WireAppili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced its financial and operational results for the third quarter of its fiscal year
4y agoAPLIF TSX:APLIAppili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis PharmaceuticalsBusiness WireAgreement expanded to add European and Latin American markets NDA filing with US FDA for Appili's ATI-1501 expected later this year Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused o
4y agoADTX APLIF TSX:APLIAditxt Signs Share Exchange Agreement to Acquire AiPharmaBusiness WireIf complete, the transaction would be the first step in establishing commercial presence in infectious disease therapeutics and transforming Aditxt into a global biotech company Aditxt Inc. (NASDAQ:ADTX), a biotech innovation company with a mission t
4y agoAPLIF TSX:APLIAppili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of DirectorsBusiness WirePositive one year challenge data builds on previously reported efficacy observed at 28- and 90-day challenge timepoints Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug developm
5y agoAPLIF TSX:APLIAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial OfficerBusiness WireAppili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2022, wh
5y agoAPLIF TSX:APLIAppili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™Business WireAppili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the Phase 3 PRESECO (PREventing SEvere COVID-19) clinical trial evaluatin
5y agoADTX APLIF RDYAiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tablet Avigan / Reeqonus / Qifenda That Has Treated Over 1.5M COVID-19 Patients Since The Outbreak.PR NewswireDUBAI, United Arab Emirates, Oct. 5, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma") a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases today announced it ha
5y agoADTX APLIF RDY TSX:APLIAditxt Signs a Transaction Agreement to Acquire AiPharma, Rights Holder of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of Over 1.5 Million COVID-19 Patients Outside the U.S. and CanadaBusiness WirePhase 3 clinical trial of Avigan/Reeqonus for treatment of COVID-19 completed enrollment of more than 1,200 patients in the U.S., Mexico and Brazil with topline results expected in less than 60 days Aditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a biotech in
5y agoAPLIFAiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili TherapeuticsPR NewswireDUBLIN, Sept. 29, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma"), a private biopharmaceutical research, development, and commercialization company, and Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) ("Appili"), a biopharmaceutical comp
5y agoAPLIF TSX:APLIAppili Therapeutics and AiPharma Announce Strategic Alliance and Equity TransactionBusiness WireStrategic alliance for the global development of oral antiviral medicine Avigan®/ReeqonusTM (favipiravir) for the treatment of COVID-19 and other infectious disease programs New agreement with existing consortium partner AiPharma enhances complement
5y agoAPLIF TSX:APLIAppili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19Business WireMore than 1,200 patients enrolled in the United States, Mexico, and Brazil Study expected to include patients with top priority COVID-19 variants, including Delta Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biop
5y agoAPLIF TSX:APLIAppili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 PatientsBusiness WireNew Funds Will Help Expedite Completion of Recently Expanded Pivotal Phase 3 Study on Oral Antiviral Medicine Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for in
5y agoAPLIF TSX:APLIAppili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 PatientsBusiness WireViral shedding sub-study to assess efficacy against recent COVID-19 variants, including Delta Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious disease
5y agoAPLIF TSX:APLIAppili Therapeutics Announces Results for Resolutions at Annual General Meeting of ShareholdersBusiness WireCapital Markets Veteran Josef Vejvoda to Join Appili Board of Directors as New Director Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, tod
5y agoAPLIF TSX:APLIAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2022Business WireAppili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the first quarter of its fiscal year 2022, whi
5y agoAPLIF TSX:APLIAppili Therapeutics Reports Fiscal Year 2021 Financial and Operational Results and Provides Update on Strategy for Fiscal 2022Business WireAppili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the fiscal year ended March 31, 2021, an
5y agoAPLIF TSX:APLI TSXV:APLIAppili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and BrazilBusiness WireAppili Also Provides Additional Trial Updates Appili Therapeutics Inc. (TSX:APLI) (OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, has added several clinical research sites in
5y agoAPLIFIndependent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan®/Reeqonus™ Trial for Mild-to-Moderate COVID-19 PatientsPR NewswireHALIFAX, NS, May 17, 2021 /PRNewswire/ -- Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced that an independent Data and Safety
5y agoAPLIF TSX:APLIAppili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021Business WireAppili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that the Company's Chief Executive Officer, Dr. Armand Balboni will present at the fully vir